<b>Conclusions:</b> Rezivertinib demonstrated a statistically significant superior CNS efficacy over gefitinib as first-line treatment in advanced <i>EGFR</i>-mutated non-small cell lung cancer patients with baseline CNS metastases. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.